SFI
VIR icon

Susquehanna Fundamental Investments’s Vir Biotechnology VIR Stock Holding History

Susquehanna Fundamental Investments’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-15,159
Closed -$91.4K – 691
2025
Q4 		$91.4K Sell
15,159
-248,738
-94% -$1.48M ﹤0.01% 537
2025
Q3 		$1.51M Sell
263,897
-36,460
-12% -$186K 0.06% 274
2025
Q2 		$1.51M Sell
300,357
-31,444
-9% -$169K 0.04% 386
2025
Q1 		$2.15M Buy
331,801
+130,616
+65% +$1.16M 0.03% 512
2024
Q4 		$1.48M Buy
+201,185
New +$1.59M 0.02% 608
2024
Q2 		$135K Buy
+15,200
New +$146K ﹤0.01% 881
2021
Q1 		– Sell
-14,211
Closed -$381K – 1618
2020
Q4 		$381K Buy
+14,211
New +$462K 0.01% 1192

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
GP
GSK plc London $602M AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Susquehanna Fundamental Investments's VIR Position: Q1 2026 in Review

Susquehanna Fundamental Investments sold out of Vir Biotechnology (VIR) in Q1 2026, closing a stake of 15,159 shares — an estimated $91.4K sold.

Susquehanna Fundamental Investments first reported a position in VIR in Q4 2020 and held it in 7 quarters. The position peaked at $2.15M in Q1 2025. 252 funds tracked by Wall St. Rank hold VIR as of Q1 2026.

  • Susquehanna Fundamental Investments reported no remaining Vir Biotechnology position as of Q1 2026 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 15,159 Vir Biotechnology shares in Q1 2026, an estimated $91.4K.
  • Susquehanna Fundamental Investments first reported a position in Vir Biotechnology in Q4 2020 and held it in 7 quarters.
  • Susquehanna Fundamental Investments's Vir Biotechnology position peaked at $2.15M in Q1 2025.
  • 252 funds tracked by Wall St. Rank held Vir Biotechnology as of Q1 2026.

Based on Susquehanna Fundamental Investments's 13F filing for Q1 2026, filed 15 May 2026.